Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Amgen Inc., GlaxoSmithKline, and Sanofi Genzyme.

Medical Crossfire®: Assessing the Role of Novel Therapies and Combinations in Relapsed/Refractory Multiple Myeloma

Release Date: May 29, 2020
Expiration Date: May 29, 2021

Activity Overview

The Medical Crossfire®, one of PER’s signature educational formats, is a video-based program in which a panel of distinguished experts engage in spirted discussions and debates on a particular clinical topic. In this activity, four key thought leaders explore the latest data regarding novel therapies and combinations for the management of relapsed/refractory multiple myeloma. This lively discussion will help place new developments into clinical context to help you optimize care for your patients with relapsed/refractory multiple myeloma.

Acknowledgement of Support

This activity is supported by educational grants from Amgen Inc., GlaxoSmithKline, and Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This activity is intended for hematologist/oncologists and medical oncologists who treat multiple myeloma. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with multiple myeloma are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Recognize disease- and patient-related factors that need to be evaluated in planning and sequencing therapies in patients with relapsed/refractory (R/R) multiple myeloma (MM)
  • Examine mechanisms of action of novel investigational therapies and the rationale supporting their utility in the treatment of patients with R/R MM
  • Assess the potential impact of investigational therapies on the evolving standard of care in the treatment of patients with R/R MM

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Ajai Chari, MD
Ajai Chari, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director of Clinical Research, Multiple Myeloma Program
Associate Director, Mount Sinai Cancer Clinical Trials Office
The Mount Sinai Hospital
New York, NY

Disclosures: Grant Research Support: Amgen, Array BioPharma, Celgene, GlaxoSmithKline, Janssen, Millennium/Takeda, Novartis Pharmaceuticals, Oncoceutics, Pharmacyclics, Seattle Genetics; Consultant: Amgen, Bristol Myers Squibb, Celgene, Millennium/Takeda, Janssen, Karyopharm Therapeutics; Other: Scientific Advisory Boards: Amgen, Celgene, Millennium/Takeda, Janssen, Karyopharm Therapeutics, Sanofi, Seattle Genetics.

Suzanne Lentzsch, MD, PhD
Suzanne Lentzsch, MD, PhD
Professor of Medicine
Columbia University Medical Center
Director, Multiple Myeloma and Amyloidosis Program
New York, NY

Disclosures: Consultant: Sorrento (DSMB), Bristol Myers Squibb (Advisory Board), Janssen, Takeda, Sanofi, Celvlarity; Stock Shareholder: Caelum Biosciences; Other (Research Funding): Sanofi, Karyopharm Therapeutics.

Deepu Madduri, MD
Deepu Madduri, MD
Assistant Director, Cellular Therapy Service
Assistant Professor of Medicine Hematology and Medical Oncology
Icahn School of Medicine at Mount Sinai Hospital
New York, NY

Disclosures: Consultant: AbbVie, Celgene, Foundation Medicine, FMI, GlaxoSmithKline, Janssen, Legend, Takeda.

Giada Bianchi, MD
Giada Bianchi, MD
Associate Director, Amyloidosis Program
Brigham and Women’s/Dana-Farber Cancer Institute
Instructor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Other: Pfizer advisory board participation.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
3031
Filter By